These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35671543)

  • 1. Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
    Schubert NA; Chen CY; Rodríguez A; Koster J; Dowless M; Pfister SM; Shields DJ; Stancato LF; Vassal G; Caron HN; van den Boogaard ML; Henssen AG; Molenaar JJ
    Eur J Cancer; 2022 Jul; 170():196-208. PubMed ID: 35671543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.
    Keller KM; Krausert S; Gopisetty A; Luedtke D; Koster J; Schubert NA; Rodríguez A; van Hooff SR; Stichel D; Dolman MEM; Vassal G; Pfister SM; Caron HN; Stancato LF; Molenaar JJ; Jäger N; Kool M
    Eur J Cancer; 2022 Feb; 162():107-117. PubMed ID: 34963094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.
    Schubert NA; Lowery CD; Bergthold G; Koster J; Eleveld TF; Rodríguez A; Jones DTW; Vassal G; Stancato LF; Pfister SM; Caron HN; Molenaar JJ
    Eur J Cancer; 2020 May; 130():168-181. PubMed ID: 32224415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune contexture of paediatric cancers.
    Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
    Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.
    Molenaar JJ; Ebus ME; Koster J; van Sluis P; van Noesel CJ; Versteeg R; Caron HN
    Cancer Res; 2008 Apr; 68(8):2599-609. PubMed ID: 18413728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
    Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MINUTE CHROMATIN BODIES IN MALIGNANT TUMOURS OF CHILDHOOD.
    COX D; YUNCKEN C; SPRIGGS AI
    Lancet; 1965 Jul; 1(7402):55-8. PubMed ID: 14304929
    [No Abstract]   [Full Text] [Related]  

  • 10. Guide for paediatric radiotherapy procedures.
    Laprie A; Bernier V; Padovani L; Martin V; Chargari C; Supiot S; Claude L
    Cancer Radiother; 2022; 26(1-2):356-367. PubMed ID: 34969622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
    Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
    Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
    Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
    Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
    Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM
    Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
    Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
    Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion.
    Bishop E; Dimitrova M; Froggatt A; Estevez-Cebrero M; Storer LCD; Mussai F; Paine S; Grundy RG; Dandapani M
    Biomed Res Int; 2022; 2022():9008685. PubMed ID: 35782058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting under the skin: The role of CDK4/6 in melanomas.
    Guo L; Qi J; Wang H; Jiang X; Liu Y
    Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of PARP as a therapeutic target across pediatric solid malignancies.
    Keller KM; Koetsier J; Schild L; Amo-Addae V; Eising S; van den Handel K; Ober K; Koopmans B; Essing A; van den Boogaard ML; Langenberg KPS; Jäger N; Kool M; Pfister S; Dolman MEM; Molenaar JJ; van Hooff SR
    BMC Cancer; 2023 Apr; 23(1):310. PubMed ID: 37020198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.